EudraGMP Homepage      
 
 
MIA | GMP | API REG | WDA | GDP | Sites Help
Thu 2 Apr 2026 09:46:26 BST
GMP Compliance Menu 
Search
GMP Certificates
Non-Compliance Report


Print Preview
                  
Print Preview (Short version)
                  
Back To Search

 

Austrian Federal Office For Safety In Health Care

CERTIFICATE NUMBER: 483078-102675507

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1) , (2)

Part 1

Issued following an inspection in accordance with
Art. 94(1) of Regulation (EU) 2019/6 as amended
Art. 63 of Regulation (EU) 536/2014 as amended
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Austria confirms the following:

The manufacturer: G.L. Pharma GmbH

Site address: Gansterergasse 9-13, Ottakring, Vienna, 1160

OMS Organisation Id. / OMS Location Id.: ORG-100000592 / LOC-100003326


Has been inspected under the national inspection programme in connection with manufacturing authorisation no.  483078  in accordance with Art. 88 of Regulation (EU) 2019/6, Art. 61 of Regulation (EU) No 536/2014 and Art. 40 of Directive 2001/83/EC, transposed in the following national legislation:§ 63 Medicines Act (Arzneimittelgesetz) and Ordinance 2009 (Arzneimittelbetriebsordnung 2009).


From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on  2025-01-10 , it is considered that it complies with:

  • The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2. (3)
  • The principles and guidelines of Good Manufacturing Practice laid down in Directive 91/412/EEC. (3)  

  • This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (https://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.

     The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

    __________________________________________________________________________________________________________________________
    (1) The certificate referred to in paragraph Art. 80(5) of Directive 2001/82/EC, Art. 15 of Directive 2001/20/EC and Art. 111(5) of Directive 2001/83/ECis also applicable to importers.
    (2) Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.
    (3) These requirements fulfil the GMP recommendations of WHO.

    Part 2

    Human Medicinal Products
    Human Investigational Medicinal Products
    Veterinary Medicinal Products

    1  MANUFACTURING OPERATIONS
    1.1  Sterile products
       1.1.3  Batch certification
    1.2  Non-sterile products
       1.2.1  Non-sterile products (processing operations for the following dosage forms)
               1.2.1.5  Liquids for external use
               1.2.1.6  Liquids for internal use
       1.2.2  Batch certification
    1.3  Biological medicinal products (list of product types)
       1.3.2  Batch Certification (list of product types)
               1.3.2.6  Human or animal extracted products
    1.4  Other products or manufacturing activity
       1.4.3  Other: Verblindung / Blinding, Montage von Injektoren und Inhalern / Assembling of injectors and inhalers, Lagerung / Storage, Verblindung / Blinding, Montage von Injektoren und Inhalern / Assembling of injectors and inhalers, Lagerung / Storage(en)
    1.5  Packaging
       1.5.1  Primary Packaging
               1.5.1.1  Capsules, hard shell
               1.5.1.2  Capsules, soft shell
               1.5.1.5  Liquids for external use
               1.5.1.6  Liquids for internal use
               1.5.1.8  Other solid dosage forms: Pulver / Powder, Pulver / Powder(en)
               1.5.1.13  Tablets
       1.5.2  Secondary packaging
    1.6  Quality control testing
       1.6.3  Chemical/Physical

    2  IMPORTATION OF MEDICINAL PRODUCTS
    2.2  Batch certification of imported medicinal products
       2.2.1  Sterile products
               2.2.1.1  Aseptically prepared
               2.2.1.2  Terminally sterilised
       2.2.2  Non-sterile products
       2.2.3  Biological medicinal products
               2.2.3.6  Human or animal extracted products
    2.3  Other importation activities
       2.3.1  Site of physical importation

    Clarifying remarks (for public users):
    Hersteller Arzneimittel: G.L. Pharma GmbH; INS-483078-103728019 Probebetrieb bis zum: / Regarding inspection case INS-483078-103728019 valid until: 31.05.2026; Hersteller klinischer Prüfpräparate: G.L. Pharma GmbH; INS-483078-103728019 Probebetrieb bis zum: / Regarding inspection case INS-483078-103728019 valid until: 31.05.2026;

     

     



     
     
     
         
     
     
     
     
    The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.

    Documents issued by UK authorities up to and including 31 December 2020 remain available for consultation in EudraGMDP. However, they are no longer included or updated from 1 January 2021, with the exception of the documents pertaining to sites located in Northern Ireland.

    [EMA © 2014. EudraGMDP 6.5.4.8 build 2026/01/16 09:45]